Comparison of   1 -testololactone (NSC-23759) and an estrogen-progestin combination (NSC-77622) in the treatment of metastatic breast cancer.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004958:Estradiol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D007783:Lactones / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D010616:Phenanthrenes / Q000627:therapeutic use*; D013738:Testolactone / Q000627:therapeutic use
D000970:Antineoplastic Agents; D004338:Drug Combinations; D006908:Hydroxyprogesterones; D007783:Lactones; D010616:Phenanthrenes; D004958:Estradiol; D013738:Testolactone